Hospital Acquired Infections Therapeutic Market

Hospital Acquired Infections Therapeutic Market by Drug Classes (Antibacterial Drugs [ Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, and Others], Antiviral Drugs, and Antifungal Drugs), Infection Types (Bloodstream Infections, Ventilator-associated Pneumonia, Urinary Tract Infections, Surgical Site Infections, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1226
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 194
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global hospital acquired infections therapeutic market size was valued at USD 10.59 billion in 2020 and is projected to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising R&D initiatives, high occurrence of hospital acquired infections and approval & launch of new therapies.
 

Hospital Acquired Infections Therapeutic Market Key Takeaways


Hospital acquired infection (HAI), also known as nosocomial infection, is mainly caused by viral, bacterial, and fungal pathogens at the time of getting treatment or during patients’ stay in healthcare facilities. High occurrence of the disease and rising resistance for antibiotic availability are increasing the demand for novel HAI therapeutics. Moreover, key market players are extensively investing in R&D activities for the development of new HAI drugs and other treatment equipment. For instance, the US Food and Drug Administration (FDA), in June 2019, approved Zerbaxa (Ceftolozane and Tazobactam) as an expanded indication of Merck & Co., Inc.’s drug for the treatment of ventilator-associated bacterial pneumonia (HABP/VABP) and hospital acquired bacterial pneumonia.

Recently, chronic diseases such as heart disease, arthritis, cancer, and diabetes are becoming major health issues with rising occurrence across globe. This leads to rise in hospital admissions. For instance, in November 2019, the New York State Department of Health published a data stating that around 40% of adults in New York suffered from chronic diseases, which has led to increase number of hospitalizations. Hence, growing hospitalizations is expected to rise in more cases of HAIs that helps the market growth of HAIs therapeutics. Over the recent years, the prevalence of HAIs have decreased comparatively in developed economies owing to the strict norms and regulations implemented by government, mandating to boost the management of hygiene and cleanliness in the healthcare facilities. In 2018, the Centers for Disease Control and Prevention (CDC) published a Healthcare-associated Infections Progress Report that stated, the central line-associated bloodstream infections were reduced by 9% in acute-care hospitals and also Clostridium difficile infections reduced by 12% in the US. The decline in the infection rate in the country is due to several improvement in healthcare management norms by the government.

Market Trends, Drivers, Restraints, and Opportunities

  • Rising prevalence of chronic diseases with required to prolonged stay in hospitals is projected to drive the market expansion.
  • Poor training and infection control practices, low expenditure on healthcare, and poor hospital infrastructure are anticipated to push the market growth during the forecast period.
  • Environmental factors such as infected materials and bacterial load in hospitals and presence of other diseases are anticipated to fuel the market growth.
  • Introduction of strict regulations from government bodies to ensure clean and healthy management of hospitals especially in the developed regions is key factors expected to hamper the market growth.
  • Rising precautionary measures and increasing awareness among staff and professionals in hospitals are projected to impede the market growth.

Scope of the Report

The report on the global hospital acquired infections therapeutic market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Hospital Acquired Infections Therapeutic Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Drug Classes (Antibacterial Drugs [Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, and Others], Antiviral Drugs, and Antifungal Drugs), Infection Types (Bloodstream Infections, Ventilator-associated Pneumonia, Urinary Tract Infections, Surgical Site Infections, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Merck & Co., Inc., Pfizer Inc., Bayer AG, GlaxoSmithKline Plc., Daiichi Sankyo Company, Ltd., AbbVie Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Allergan Plc.

 

Market Segment Insights

Antibacterial drugs segment is expected to expand at a rapid pace
On the basis of drug classes, the hospital acquired infections therapeutic market is segmented into antibacterial drugs, antiviral drugs, and antifungal drugs. The antibacterial drugs segment is further divided into cell wall synthesis inhibitors, protein synthesis inhibitors, and others. The antibacterial drugs segment is expected to hold a key share of the market during the forecast period due to large number of HAIs are caused by bacteria. The drug type is considered to be one of the primary treatment and most commonly adopted for the disease treatment. Patients who are affected with gram-positive and gram-negative pathogens are treated with antibiotics. For multidrug-resistant pathogens treatment, empiric antibiotic therapy is initially considered and is highly used for avoiding complications such as bloodstream infections, renal damage, and pyelonephritis.

Surgical site infections segment is projected to hold a key market share
Based on infection types, the market is segmented into bloodstream infection (BSI), Pneumonia, urinary tract infection (UTI), and surgical site infection (SSI). The SSIs segment dominated the market in 2020 and is expected to hold a key share of the market during the forecast period owing to growing number of SSI cases subsequently and increasing number of surgical procedures. According to the CDC, each year nearly around 27 million surgical procedures are performed out of which around 5% of patients got SSIs in the US. Due to this reason, the patient’s hospitalization is normally lasted for 7 to 10 days and average cost is around USD 3,000 per patient.

On the other hand, the UTIs segment is anticipated to expand at a rapid pace during the forecast period due to increasing cases of UTI and growing awareness among people in developed countries. Kidney, ureters, urethra, and bladder are affected by UTIs and around 40% of the population have had the experience of UTI condition for several period of time. As per a report by National Healthcare Safety Network, the common type of UTI is Catheter-associated UTIs (CA-UTIs) and as per CDC 2017 data, CA-UTIs accounted for around two-thirds of the UTIs. Furthermore, introducing novel drugs for UTI is a major factor responsible for fuel the HAIs therapeutics market growth.
 

Hospital Acquired Infections Therapeutic Market byInfection Types


Europe is anticipated to dominate the market
On the basis of regions, the hospital acquired infections therapeutic market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of Europe is anticipated to dominate the market at an impressive CAGR during the forecast period. The regional market growth can be attributed to occurrence of HAIs in this region and rising introduction of novel HAI therapeutic drugs owing to presence of local key players such as GlaxoSmithKline Plc., F. Hoffmann-La Roche AG., Allergan Plc., and Bayer AG.

On the other hand, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to growing occurrence of chronic diseases in emerging countries such as India and China, which lead to rise in the number of hospitalization in these countries. For instance, Globocan published a data in 2018, in China around 4,285,000 new cases of cancer were diagnosed. Hence, rising rate of HAIs with growing hospitalizations in the region is projected to increase the demand for HAI therapeutic market in Asia Pacific.
 

Hospital Acquired Infections Therapeutic Market by Regions

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Hospital Acquired Infections Therapeutic Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Hospital Acquired Infections Therapeutic Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Hospital Acquired Infections Therapeutic Market - Supply Chain
  4.5. Global Hospital Acquired Infections Therapeutic Market Forecast
     4.5.1. Hospital Acquired Infections Therapeutic Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Hospital Acquired Infections Therapeutic Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Hospital Acquired Infections Therapeutic Market Absolute $ Opportunity
5. Global Hospital Acquired Infections Therapeutic Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Hospital Acquired Infections Therapeutic Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Hospital Acquired Infections Therapeutic Demand Share Forecast, 2019-2026
6. North America Hospital Acquired Infections Therapeutic Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Hospital Acquired Infections Therapeutic Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Hospital Acquired Infections Therapeutic Demand Share Forecast, 2019-2026
7. Latin America Hospital Acquired Infections Therapeutic Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Hospital Acquired Infections Therapeutic Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Hospital Acquired Infections Therapeutic Demand Share Forecast, 2019-2026
8. Europe Hospital Acquired Infections Therapeutic Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Hospital Acquired Infections Therapeutic Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Hospital Acquired Infections Therapeutic Demand Share Forecast, 2019-2026
9. Asia Pacific Hospital Acquired Infections Therapeutic Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Hospital Acquired Infections Therapeutic Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Hospital Acquired Infections Therapeutic Demand Share Forecast, 2019-2026
10. Middle East & Africa Hospital Acquired Infections Therapeutic Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Hospital Acquired Infections Therapeutic Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Hospital Acquired Infections Therapeutic Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Hospital Acquired Infections Therapeutic Market: Market Share Analysis
  11.2. Hospital Acquired Infections Therapeutic Distributors and Customers
  11.3. Hospital Acquired Infections Therapeutic Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Merck & Co., Inc.
     11.4.2. Pfizer Inc.
     11.4.3. Bayer AG
     11.4.4. GlaxoSmithKline Plc.
     11.4.5. Daiichi Sankyo Company, Ltd.

Segments Covered in the Report
The global hospital acquired infections therapeutic market has been segmented on the basis of

Drug Classes

  • Antibacterial Drugs
    • Cell Wall Synthesis Inhibitors
    • Protein Synthesis Inhibitors
    • Others
  • Antiviral Drugs
  • Antifungal Drugs

Infection Types

  • Bloodstream Infections (BSI)
  • Ventilator-associated Pneumonia
  • Urinary Tract Infections (UTI)
  • Surgical Site Infections (SSI)
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Merck & Co., Inc.
  • Pfizer Inc.
  • Bayer AG
  • GlaxoSmithKline Plc.
  • Daiichi Sankyo Company, Ltd.
  • AbbVie Inc.
  • Abbott Laboratories
  • F. Hoffmann-La Roche Ltd.
  • Allergan Plc.

Key players competing in the hospital acquired infections therapeutic market include Merck & Co., Inc., Pfizer Inc., Bayer AG, GlaxoSmithKline Plc., Daiichi Sankyo Company, Limited, AbbVie Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd, and Allergan Plc.

Some of these major players are constantly focusing on business strategies including as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares. For instance, in March 2017, a US-based multinational pharmaceutical company, Pfizer Inc. has introduced its drug Zavicefta (Ceftazidime-Avibactam) in the UK and Germany. This drug was approved for different indications including hospital-acquired pneumonia (HAP).
 

Hospital Acquired Infections Therapeutic Market by Key Players

Buy Report